Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Actemra Approval Expanded Amid Increasing Safety Concerns September 5, 2017 Irvin Jackson Add Your Comments Despite growing concerns the side effects of Actemra, and questions about whether the rheumatoid arthritis drug warnings are adequate, federal regulators have approved the expanded use of the medication to treat severe or life-threatening cytokine release syndrome (CRS), caused by CAR-T therapy. Roche issued a press release on August 30, announcing the FDA’s decision to expand approval for Actemra and RoActemra as a treatment for cell-induced cytokine release syndrome caused by CAR-T, which is a cell immunotherapy treatment used to treat some types of cancers. Cytokine release syndrome is an overactive immune response that ranges from flu-like symptoms to life threatening complications, such as heart problems, acute respiratory distress or multiple organ failure. Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Actemra (tocilizumab) was introduced in 2010, as a second-line treatment for rheumatoid arthritis, in severe cases where individuals have not responded to other drugs. In May 2017, the FDA approved expanded use to treat giant cell arteritis, and the medication has grown to generate over $1.6 billion in annual sales. This latest approval means that the drug can be marketed by Roche to even more patients, who would also be exposed to the potential side effects, including those that some say are not adequately disclosed on the label. Unlike other competing rheumatoid arthritis drugs, Actemra warnings do not include information about certain health risks linked to competing treatments, such as Humira, Remicade and Enbrel. Therefore, many doctors and consumers are under the impression that Actemra is safer. However, recent reports suggest that users may face the same, or higher risks. A recent independent review of adverse event reports submitted to the FDA identified a higher-than-expected number of severe injuries, including heart attacks, strokes, heart failure, interstitial lung disease and pancreatitis. In addition, the drug has been linked to at least 1,128 deaths since 2010. As a result, some are calling for Actemra warnings to be added, which may cut into sales. A number of product liability lawyers are now reviewing the potential for Actemra lawsuits for individuals who have experienced problems, suggesting that Roche new or should have known that the drug carried similar risks to other rheumatoid arthritis drugs, but withheld information from the label to create a false impression that their drug was safer. Tags: Actemra, Heart Attack, Infection, Pancreatitis, Roche, Stroke More Actemra Lawsuit Stories Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018 Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018 Actemra Unfit For Use Against Giant Cell Arthritis, UK Regulators Rule December 11, 2017 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025) 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018
Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018
Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)